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Abstract
Background
The prevalence of and mortality from HIV-associated tuberculosis (HIV/TB) in hospital inpa-
tients in Africa remains unacceptably high. Currently, there is a lack of tools to identify those
at high risk of early mortality who may benefit from adjunctive interventions. We therefore
aimed to develop and validate a simple clinical risk score to predict mortality in high-burden,
low-resource settings.
Methods and findings
A cohort of HIV-positive adults with laboratory-confirmed TB from the STAMP TB screening
trial (Malawi and South Africa) was used to derive a clinical risk score using multivariable
predictive modelling, considering factors at hospital admission (including urine lipoarabino-
mannan [LAM] detection) thought to be associated with 2-month mortality. Performance
was evaluated internally and then externally validated using independent cohorts from 2
other studies (LAM-RCT and a Me´decins Sans Frontières [MSF] cohort) from South Africa,
Zambia, Zimbabwe, Tanzania, and Kenya. The derivation cohort included 315 patients
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enrolled from October 2015 and September 2017. Their median age was 36 years (IQR 30–
43), 45.4% were female, median CD4 cell count at admission was 76 cells/μl (IQR 23–206),
and 80.2% (210/262) of those who knew they were HIV-positive at hospital admission were
taking antiretroviral therapy (ART). Two-month mortality was 30% (94/315), and mortality
was associated with the following factors included in the score: age 55 years or older, male
sex, being ART experienced, having severe anaemia (haemoglobin < 80 g/l), being unable
to walk unaided, and having a positive urinary Determine TB LAM Ag test (Alere). The score
identified patients with a 46.4% (95% CI 37.8%–55.2%) mortality risk in the high-risk group
compared to 12.5% (95% CI 5.7%–25.4%) in the low-risk group (p < 0.001). The odds ratio
(OR) for mortality was 6.1 (95% CI 2.4–15.2) in high-risk patients compared to low-risk
patients (p < 0.001). Discrimination (c-statistic 0.70, 95% CI 0.63–0.76) and calibration
(Hosmer-Lemeshow statistic, p = 0.78) were good in the derivation cohort, and similar in the
external validation cohort (complete cases n = 372, c-statistic 0.68 [95% CI 0.61–0.74]). The
validation cohort included 644 patients between January 2013 and August 2015. Median
age was 36 years, 48.9% were female, and median CD4 count at admission was 61 (IQR
21–145). OR for mortality was 5.3 (95% CI 2.2–9.5) for high compared to low-risk patients
(complete cases n = 372, p < 0.001). The score also predicted patients at higher risk of
death both pre- and post-discharge. A simplified score (any 3 or more of the predictors) per-
formed equally well. The main limitations of the scores were their imperfect accuracy, the
need for access to urine LAM testing, modest study size, and not measuring all potential
predictors of mortality (e.g., tuberculosis drug resistance).
Conclusions
This risk score is capable of identifying patients who could benefit from enhanced clinical
care, follow-up, and/or adjunctive interventions, although further prospective validation stud-
ies are necessary. Given the scale of HIV/TB morbidity and mortality in African hospitals,
better prognostic tools along with interventions could contribute towards global targets to
reduce tuberculosis mortality.
Author summary
Why was this study done?
• HIV-associated tuberculosis (TB) is very common in hospitals in sub-Saharan Africa,
and is a major cause of morbidity and mortality.
• There is a lack of tools to identify which patients are more likely to die early; therefore,
these patients cannot be targeted for more intensive clinical care or other treatments in
addition to TB antibiotics and antiretroviral drugs.
• A new urine TB diagnostic test (detecting a substance called lipoarabinomannan
[LAM]) can identify patients at higher risk of dying and, along with other simply mea-
sured clinical signs or symptoms, may be useful for predicting which patients are most
likely to do poorly.
Clinical risk score to predict mortality in inpatients with HIV-associated tuberculosis
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What did the researchers do and find?
• We used data from HIV-positive adults admitted to hospital in Malawi and South Africa
and diagnosed with TB to develop a simple clinical risk score to identify patients with a
50% chance of dying within 2 months.
• The score included 6 factors that can be measured at admission to hospital, including
the results of the urine TB test, presence of anaemia, and some demographic factors.
• We then tested the performance of the risk score using data from studies of different
patients from sub-Saharan Africa, and it performed similarly.
• The score was able to identify patients at higher risk of dying during admission to hospi-
tal, and after discharge from hospital.
What do these findings mean?
• This score could be used to identify patients admitted to hospital and diagnosed with
HIV-associated TB who may benefit most from more intensive clinical care, additional
treatments, and/or closer follow-up after discharge.
• It could also be used as a research tool to study new drugs or strategies aimed at reduc-
ing mortality from with HIV-associated TB.
• This is the first such tool to our knowledge in this patient population, and future studies
could optimise such predictive tools, in particular if appropriate new interventions and/
or diagnostics become available.
Introduction
Tuberculosis (TB) is the leading infectious disease killer globally, causing an estimated 1.7 mil-
lion deaths globally in 2017 [1]. This burden lies disproportionately in people living with HIV,
who account for approximately 1 in 4 TB deaths. The case fatality rate of HIV-associated TB
(HIV/TB) is particularly high in hospitals, estimated at 29% in a recent meta-analysis [2]. This
may be an underestimate, given that post-mortem studies from sub-Saharan Africa have dem-
onstrated that a high proportion of HIV-positive deaths in facilities have evidence of undiag-
nosed TB [3].
Interventional studies aiming to reduce mortality in this patient population have demon-
strated mortality reductions with improved TB diagnostics [4,5] and appropriately timed initi-
ation of antiretroviral therapy (ART) [6,7]. However, mortality remains substantial despite
these interventions, and adjunctive interventions are likely to be needed to further impact
mortality. Currently, predictors for mortality are poorly defined. Being able to identify patients
at the highest risk of mortality could inform the development and assessment of new interven-
tions, and also identify which patients would benefit most from interventions beyond TB ther-
apy and appropriately timed ART [8].
Clinical decision tools and risk scores are used widely in clinical practice to simplify the
identification of patients at highest risk for poor health outcomes. Predictor scores for
Clinical risk score to predict mortality in inpatients with HIV-associated tuberculosis
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mortality have been developed for HIV-associated cryptococcal meningitis and pneumonia,
and are used to guide management in Pneumocystis jiroveci pneumonia [9–11]. Although
scores have been developed to predict risk of TB disease in various populations, including TB
bacteraemia in hospitalised patients [12], to our knowledge no externally validated scores exist
to predict outcomes of TB disease among hospitalised patients with HIV [13,14]. Scores devel-
oped to predict TB mortality in settings with low HIV prevalence are also of limited use in peo-
ple living with HIV due to differences in clinical presentation, pathogenesis, and outcomes
[15–18]. A recent study from the US developed and internally validated a score to predict mor-
tality in HIV/TB in low-prevalence settings (US), but this would not be applicable to hospital-
ised patients in Africa given that many of the variables are not routinely available [19].
We have previously shown that detection of lipoarabinomannan (LAM) in the urine of
HIV/TB patients using a cheap (approximately US$3) and quick (testing takes 25 minutes) lat-
eral flow assay is independently associated with a 2- to 3-fold increased risk of mortality [20].
We therefore aimed to investigate if urinary LAM detection, along with other clinical variables
readily available in high-burden settings, could be used to predict which HIV-positive patients
admitted to hospital and diagnosed with TB were at high risk of early mortality, and to exter-
nally validate the predictive tool.
Methods
Study design and participants for prediction tool development
We used data from the STAMP (‘rapid urine-based screening for tuberculosis in HIV-positive
patients admitted to hospital in Africa’) trial for the clinical risk score derivation [5,21]. The
STAMP trial recruited HIV-positive adults (aged 18 years or more), irrespective of symptoms
or clinical presentation, who were admitted to medical wards of 2 hospitals in Malawi and
South Africa between 26 October 2015 and 19 September 2017. On admission, patients were
screened for TB using Xpert MTB/RIF (Xpert; Cepheid) on sputum in both study arms, and
Xpert and Determine TB LAM Ag (TB-LAM; Alere) assays on urine in the intervention arm.
Exclusion criteria in the trial were already taking TB treatment and inability to give consent.
The clinical teams managing the patients were masked to which TB tests were positive; there-
fore, management of TB patients should not have differed between arms. The management of
HIV/TB in the study hospitals was representative of their local settings and followed local and
national guidelines, with no input from the study team (beyond TB diagnostic tests).
Patients diagnosed with TB in the standard-of-care arm had stored urine tested with Xpert
and TB-LAM retrospectively. Data were collected at baseline (at or close to admission) on
demographics and clinical characteristics, and subsequently on TB investigations and treat-
ment, and clinical events, including death or discharge from hospital. Patients discharged alive
were followed up at 2 months by outpatient attendance, home visit, or telephone for vital sta-
tus. The derivation cohort included all patients (from both trial arms) with laboratory-con-
firmed TB. The outcome was mortality risk at 2 months after admission. Patients lost to
follow-up were assumed alive at 56 days.
Definitions
Laboratory-confirmed TB was defined as any 1 of a positive smear microscopy, mycobacterial
culture, Xpert from any site, or urinary TB-LAM. TB-LAM assay was positive if recorded as
‘grade 1’ or higher on the manufacturer’s (post-2014) reference card. Ability to walk unaided
was assessed by healthcare workers (not self-reported by patients), and was equivalent to a
Karnofsky functional score below 40 points [22]. WHO danger signs were heart rate> 120
beats per minute, respiratory rate> 30 per minute, temperature > 39˚C, and being unable to
Clinical risk score to predict mortality in inpatients with HIV-associated tuberculosis
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walk unaided. ‘ART experienced’ was defined as receiving ART at the time of enrolment to the
study.
Score derivation
Candidate predictor variables were identified for inclusion in the predictive model based on a
priori clinical knowledge, previous literature, and the need for variables to be objective, repro-
ducible, and available in resource-constrained settings [23]. We considered variables known to
be associated with mortality in HIV/TB, including age, sex, ART experience, physiological
measurements at admission, weight and/or body mass index, CD4 cell count, functional status
(being unable to walk unaided), and haemoglobin [24–28]. Time on ART was not considered
as not all patients take ART, and because of challenges in accurately ascertaining duration.
Where 2 or more predictors were highly correlated, only 1 was selected, to simplify the prog-
nostic model, as inclusion of all would contribute little additional predictive information [23].
Analyses were planned prospectively (see S1 Appendix) except where indicated as post hoc.
Continuous variables were assessed for non-linearity using fractional polynomials, and cat-
egorised based on previously established cutoffs (e.g., CD4 cell count and haemoglobin) or
associations with mortality (e.g., age and weight, using the fp plot command in Stata). Com-
plete case analysis was chosen for the derivation score as few data (<5%) were missing. We
first performed univariable analyses assessing the association of each variable with mortality
risk using logistic regression. We then used a backward elimination, stepwise approach to cre-
ate a multivariable predictive model, starting with all candidate variables, and excluding vari-
ables sequentially if p> 0.1 using likelihood ratio tests and the Akaike information criterion.
Given that there were 94 deaths, we did not want to estimate more than 9 candidate predictors
(various studies have shown each candidate predictor studied requires a minimum of 10
events) [29]. Interactions were also assessed using likelihood ratio testing. All analyses were
done using Stata version 14, and all p-values were 2-sided.
Regression coefficients from the final multivariable model were multiplied by the smallest
possible constant and then rounded to the nearest integer, and then assigned as ‘points’ to
each variable. The clinical risk score was derived by combining the points based on each
patient’s characteristics. High-, medium-, and low-risk groups for mortality were then arbi-
trarily defined after plotting risk score against observed mortality such that the high-risk
group accounted for most (>50%) deaths and the low-risk group accounted for as few deaths
as possible.
Risk score evaluation and internal performance
Mortality risk at 2 months and 95% confidence intervals (CIs) were calculated for each risk
group, as were odds ratios (ORs) and 95% CI for mortality. In exploratory analyses, inpatient
and outpatient (post-discharge) deaths were also compared between risk groups by restricting
analyses to deaths occurring during hospital admission or to deaths occurring after discharge
in the subset of patients who were discharged alive from hospital. CD4 cell count and
TB-LAM grade were also compared between risk groups. Mortality risk was compared
between groups using chi-squared tests.
We assessed the model discrimination (ability to differentiate patients who would die
within 2 months and those who would survive) by calculating the concordance index (c-statis-
tic) (also known as the area under the receiver operator curve), assuming a c-statistic < 0.6
showed poor discrimination [30]. Model calibration was assessed by plotting the probability of
mortality predicted by the model against observed mortality in the derivation dataset using a
calibration plot and the Hosmer-Lemeshow test, assuming a p< 0.05 indicated poor
Clinical risk score to predict mortality in inpatients with HIV-associated tuberculosis
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calibration. In post hoc analysis, in response to reviewer request and to better understand the
utility of the score, the sensitivity and positive predictive value of the score were calculated.
External validation
To externally validate the clinical risk score, we used data collected independently from 2 stud-
ies: (1) a multicentre diagnostic clinical trial of adjunctive urine TB-LAM testing in HIV-posi-
tive patients with TB symptoms who were admitted to hospitals in 4 sub-Saharan African
countries (South Africa, Zambia, Zimbabwe, and Tanzania) (LAM-RCT) [31] and (2) a pro-
spective cohort study assessing the diagnostic yield of TB-LAM in HIV-positive patients with
TB symptoms in Kenya (Me´decins Sans Frontières [MSF] cohort study) [32]. Patients were
included in the validation cohort if they were adults and had laboratory-confirmed TB (as pre-
viously defined). Patients from the LAM-RCT in the ‘no TB-LAM’ arm were excluded, as were
outpatients (i.e., patients not admitted to hospital) from the MSF cohort study.
The validation cohort sites were all in settings in sub-Saharan Africa with high HIV preva-
lence and TB incidence, but differed from the derivation cohort in that all patients had at least 1
TB symptom (cough, fever, weight loss, or night sweats). The LAM-RCT recruitment occurred
between 1 January 2013 and 2 October 2014, and the MSF cohort recruitment between 22 Octo-
ber 2013 and 20 August 2015. Mortality outcomes were assessed at 2 months in both studies.
The clinical risk score for mortality was calculated by assigning the same ‘points’ to vari-
ables as for the derivation cohort, and the same cutoffs were used to define high-, medium-,
and low-risk groups for mortality. Patients with missing observations were excluded, for a
complete case analysis. However, sensitivity analyses were done for score performance using
multivariate multiple imputation with chained equations for missing data as 42% of patients
had missing data in the validation cohort. Data were assumed to be missing at random, and
were imputed for missing candidate predictor variables using mortality risk, other candidate
predictor variables, and other baseline demographic variables, with 100 imputations.
Evaluation of the score in the validation dataset was done using the same statistical methods
as the internal evaluation, with calculation of mortality risk at 2 months, ORs for mortality,
and survival curves. Discrimination was assessed using the c-statistic, and calibration with a
calibration plot and the Hosmer-Lemeshow test.
The study is reported in concordance with TRIPOD guidance for multivariable prediction
models (see S2 Appendix) [33]. Ethical approval for each of the source studies was obtained
from the relevant ethics committees in the country of data collection and from the trial sponsors
(see S3 Appendix for list of ethics committees). All patients provided informed written consent.
Results
Baseline characteristics
Of 506 HIV-positive patients diagnosed with TB in the STAMP trial derivation cohort, 322
had laboratory-confirmed TB. Seven patients were excluded from the complete case analysis
for missing data (Fig 1). The median age of TB patients included in the derivation cohort was
36 years (interquartile range [IQR] 30–43), 172 (55%) were men, 53 (17%) were newly diag-
nosed with HIV, and the median CD4 cell count was 76 cells/μl (IQR 23–206; Table 1). In all,
209 (65%) patients were positive on urine TB-LAM testing, indicating probable disseminated
TB disease. Anaemia was common and median haemoglobin was 86 g/l (IQR 67–108).
Patients presented with advanced disease: 133 (42%) had 1 or more WHO danger signs, and
71 (23%) were severely disabled or unable to walk unaided.
In the derivation cohort, 94 (30%) patients died within 2 months, with 66 (70%) dying dur-
ing their hospital admission; 29 (31% of deaths) patients died by 1 week, and 52 (55%) by 2
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weeks, after admission. In unadjusted analyses, mortality risk was higher in patients aged 55
years or older, men, ART-experienced patients, those unable to walk, patients with severe
anaemia (haemoglobin < 80 g/l), patients with CD4 cell count < 100 cells/μl, and those with
positive urine TB-LAM tests (Table 2). Six out of 322 (2%) patients were lost to follow-up after
hospital discharge.
Multivariable model and clinical risk score
The final multivariable logistic regression model for mortality at 2 months included age, sex,
ART experience, haemoglobin, functional status (being unable to walk unaided), and urine
TB-LAM result (Table 2). For associations of linear continuous variables with mortality see S1
Table. CD4 count and weight were dropped from the final predictor score model as their rela-
tionship with mortality was mediated by functional status and urine TB-LAM result. We
found no significant interactions between variables in the final model. The c-statistic for the
predictive model in the derivation dataset was 0.70 (95% CI 0.63–0.76), showing moderate dis-
crimination. Calibration of the predictive model was good, as shown by the calibration plot
(see S1 Fig) and a Hosmer-Lemeshow statistic p = 0.78.
The clinical risk score for mortality, based on the regression coefficients, is outlined in Fig
2. Observed and predicted mortality risks for the risk score are reported in S2 Fig. Mortality
risk groups were defined as low risk (10 points or fewer), medium risk (11 to 20 points), or
high risk (more than 20 points) (Fig 3). Therefore, in the derivation cohort, 48 (15%) patients
were deemed low risk, 142 (45%) were deemed medium risk, and 125 (40%) were deemed
high risk. Median risk score was 19 (IQR 13–22, range 0–42). Observed mortality risk by 2
months was 12.5% (95% CI 5.7%–25.4%), 21.1% (95% CI 15.1%–28.7%), and 46.4% (95% CI
37.8%–55.2%) in the low-, medium-, and high-risk groups, respectively (p< 0.001). ORs for
mortality were 6.1 (95% CI 2.4–15.2) in the high-risk group and 1.9 (95% CI 0.7–4.8) in the
medium-risk group compared to low-risk patients (p< 0.001).
Simplified clinical risk score for mortality
As the regression coefficients and points in the clinical risk score were similar for all 6 vari-
ables, we created a simplified version of the score by assigning each variable within the score 1
Fig 1. Study profile. LAM, lipoarabinomannan; MSF, Me´decins Sans Frontières; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002776.g001
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Table 1. Baseline characteristics.
Characteristic Category Median (IQR) or N (%)
Derivation dataset (n = 315) Validation dataset (n = 644)
Demographics
Age (years) 36 (30–43) 35 (30–42)
Sex Female 143 (45.4) 315 (48.9)
Country of enrolment South Africa 162 (51.4) 102 (15.8)
Tanzania — 70 (10.9)
Zambia — 151 (23.5)
Zimbabwe — 139 (21.6)
Kenya — 182 (28.3)
Malawi 153 (48.6) —
HIV history
New HIV diagnosis Yes 53 (16.8) —
Currently taking ART Yes 210 (80.2) 290 (45.0)
Time on ART (years)a 1.0 (0.2–4.4) 0.7 (0.1–3.2)
CD4 cell count (cells/μl)b 76 (23–206) 61 (21–145)
TB history
Cough Yes 228 (72.4) 601 (93.5)
Fever Yes 223 (70.8) 562 (87.3)
Weight loss Yes 286 (90.8) 595 (95.8)
Night sweats Yes 165 (52.4) 531 (82.6)
WHO TB symptom screen Yes 310 (98.4) 644 (100)
Previous history of TB Yes 72 (22.9) 123 (19.1)
Clinical presentation
Weight (kg)c 50 (42–57) 49 (43–55)
BMId 19.1 (16.2–21.0) 17.6 (15.9–20.3)
Heart rate (bpm) 104 (90–118) 102 (90–119)
Respiratory rate (per minute) 22 (20–26) 24 (22–28)
Systolic blood pressure (mm Hg) 102 (92–116) 104 (95–116)
Temperature (˚C) 36.5 (36.1–37.2) 37.0 (36.6–38.0)
Haemoglobin (g/l)e 86 (67–108) 85 (68–100)
WHO danger signf Yes 133 (42.2) 399 (62.0)
Unable to walk unaidedg Yes 71 (22.5) 262 (40.7)
TB diagnosis
Sputum Xpert positive Yes 168 (52.2) 217 (33.7)
Sputum smear microscopy positive Yes — 211 (32.8)
TB culture positive (any site) Yes — 388 (60.3)
Urine LAM positive Yes 209 (64.9) 424 (65.8)
Chest X-ray suggestive of TB Yes 107 (33.2) 336 (52.2)
Outcome
Died by 2 months Yes 94 (29.8) 147 (22.8)
Sputum smear and TB culture were not routinely performed in the STAMP trial (derivation dataset). Missing data are for the validation dataset only.
aTime on ART missing for 19 (3%) patients.
bCD4 cell count missing for 27 (4%) patients.
cWeight missing for 75 (12%) patients.
dBMI missing for 90 (14%) patients.
eHaemoglobin missing for 272 (42%) patients.
fOne of heart rate > 120 bpm, respiratory rate > 30 per minute, temperature > 39˚C, or unable to walk unaided.
gAbility to walk unaided was assessed by healthcare worker and not self-reported.
ART, antiretroviral therapy; BMI, body mass index; bpm, beats per minute; IQR, interquartile range; LAM, lipoarabinomannan; TB, tuberculosis; WHO, World Health
Organization; Xpert, Xpert MTB/RIF.
https://doi.org/10.1371/journal.pmed.1002776.t001
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point if present (age 55 years or over, male sex, ART experienced, severe anaemia, being
unable to walk unaided, or urine TB-LAM positive; see S3 Fig). A high mortality risk was
defined as 3 or more points, medium risk as 2 points, and low risk as 0 or 1 point.
In the derivation cohort, patients with 3 or more points (high risk) had a mortality of
40.0% (70/175, 95% CI 33.0%–47.5%), compared to 19.6% (18/92, 95% CI 12.6%–29.0%)
mortality in those with 2 points and 12.5% (6/48, 95% CI 5.7%–25.4%) in those with 0 or 1
point (p < 0.001) (see Fig 3 and S2 Table). The sensitivity of the risk score for mortality in
was 0.75 (the score correctly identified 70/94 deaths), and the positive predictive value
was 0.4.
The clinical risk score was useful in predicting deaths that occurred during inpatient admis-
sion (50 [28.6%, 95% CI 22.3%–35.8%] in the high-risk group compared to 6 [10.9%, 95% CI
5.9%–19.1%] in the low-risk group, p = 0.001) as well as deaths occurring after discharge (20
[16.0%, 95% CI 10.5%–23.6%] in the high-risk group compared to 0 [0%] in the low-risk
group, p = 0.015; Fig 4). More patients in the high-risk group were TB-LAM positive and had
higher grades of positive result, but CD4 cell count did not differ by risk group (see S4 Fig).
Survival curves by risk group are presented in Fig 5.
Table 2. Univariable and multivariable logistic regression analysis of factors associated with mortality in the derivation cohort (n = 315).
Characteristic Category Dieda (n = 94) Univariable Multivariable Regression (β) coefficient
OR (95% CI) p-Value OR (95% CI) p-Value
Demographics
Age <55 years 82 (28.4) 1 (ref) 0.067 1 (ref) 0.710
�55 years 12 (46.2) 2.2 (1.0–4.9) 2.0 (0.9–4.9) 0.10
Sex Female 32 (22.4) 1 (ref) 0.012 1 (ref) 0.923
Male 62 (36.0) 2.0 (1.2–3.2) 2.5 (1.5–4.3) 0.001
HIV infection
ART experienced No 18 (20.9) 1 (ref) 0.024 1 (ref) 0.621
Yes 76 (33.2) 1.9 (1.1–3.4) 1.9 (1.0–3.5) 0.048
CD4 cell count# �100 cells/μl 31 (23.9) 1 (ref) — — —
<100 cells/μl 62 (33.9) 1.7 (1.0–2.8) 0.040 — — —
Clinical presentation
WHO danger sign No 50 (27.5) 1 (ref) 0.185 — — —
Yes 48 (34.8) 1.4 (0.9–2.2) — — —
Weight <35 kg 10 (43.5) 3.3 (1.2–8.9) 0.054 — — —
35–60 kg 73 (31.5) 1.8 (0.9–3.5) — — —
>60 kg 11 (18.3) 1 (ref) — — —
Haemoglobin (g/l) �80 g/l 44 (23.7) 1 (ref) 0.003 1 (ref) 0.703
<80 g/l 50 (38.8) 2.0 (1.3–3.3) 2.0 (1.2–3.4) 0.008
Unable to walk unaided No 64 (26.2) 1 (ref) 0.004 1 (ref) 0.689
Yes 30 (42.3) 2.2 (1.3–3.8) 2.0 (1.1–3.6) 0.022
TB diagnosis
Urine LAM positive No 24 (22.6) 1 (ref) 0.044 1 (ref) 0.603
Yes 70 (33.5) 1.7 (1.0–2.9) 1.8 (1.0–3.2) 0.040
The constant (intercept) was −2.8. p-Values were calculated by likelihood ratio tests. There was no evidence of interaction between urine LAM positivity, being unable
to walk, and haemoglobin < 80 g/l in the multivariable model (likelihood ratio test p-values all >0.1). Weight and being unable to walk were strongly associated.
aData are number of patients in category who died (%).
ART, antiretroviral therapy; LAM, lipoarabinomannan; OR, odds ratio; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002776.t002
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External validation
The external validation cohort included 644 HIV-positive patients with laboratory-confirmed
TB, of whom 372 (58%) patients had no missing data for the risk score and were therefore
included in the complete case analysis (Fig 1). Baseline characteristics were similar between
cohorts, although fewer patients reported taking ART and more patients presented with severe
functional impairment and 1 or more WHO danger signs in the validation cohort (Table 1). A
similar proportion of patients were positive on urine TB-LAM testing (65% in the derivation
cohort compared to 66% in the validation cohort). Mortality at 2 months was lower in the vali-
dation cohort (22.8%) compared to the derivation cohort (29.8%). Loss to follow-up was 4% in
the validation cohort (15/372).
In complete case analysis (n = 372), the observed mortality risks in the validation cohort
were 8.7% (95% CI 4.6%–16.0%) in the low-risk group, 19.1% (95% CI 13.2%–26.8%) in the
medium-risk group, and 35.5% (95% CI 27.9%–43.9%) in the high-risk group (see Fig 4).
Median risk score was 16 (IQR 10–22, range 0–42). The ORs for mortality by risk group were
similar to those in the derivation cohort (5.8 [95% CI 2.7–12.3] for the high-risk group and 2.5
[95% CI 1.1–5.5] for the medium-risk group compared to the low-risk group). The risk score
was also useful in predicting both inpatient and post-discharge deaths (the high-risk group
had a 20% risk of post-discharge death compared to 5% in the low-risk group). The simplified
risk score performed similarly to the full score in the validation cohort.
The predictive model had similar calibration and discrimination in the validation cohort as
in the derivation cohort: the c-statistic was 0.68 (95% CI 0.61–0.74; see S3 Table), and the Hos-
mer-Lemeshow statistic had p = 0.13 (see S5 Fig for the calibration plot). In a sensitivity analy-
sis using multiple imputation for missing data in the validation dataset (n = 644), the c-statistic
for the predictive model was 0.64 (95% CI 0.60–0.69), and the Hosmer-Lemeshow statistic had
p = 0.67. ORs for mortality were 5.3 (95% CI 2.2–9.5) for the high-risk group and 2.1 (95% CI
1.0–4.6) for the medium-risk group compared to low-risk patients (p< 0.001).
Discussion
In this study, we developed and externally validated a pragmatic clinical risk score to predict
early mortality in HIV-positive patients admitted to hospital and diagnosed with laboratory-
confirmed TB. Our score used 6 clinical and laboratory factors that could be readily collected
at admission to hospital in settings with high HIV and TB burden. The score was able to
Fig 2. Risk score calculation to predict mortality. TB, tuberculosis; TB-LAM, Determine TB LAM Ag.
https://doi.org/10.1371/journal.pmed.1002776.g002
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categorise patients into 3 risk groups. One-third of the high-risk group died during hospital
admission, and almost 50% had died by 2 months. A simplified ‘3 of 6 predictors’ version of
the score performed similarly. This is the first study to our knowledge to derive and externally
validate a risk score to predict mortality in this patient population.
We found older age, being male, being ART experienced, having severe anaemia, being
severely disabled or unable to walk unaided, and being urine TB-LAM positive were all risk
Fig 3. Distribution of risk scores and mortality in the derivation dataset. Distribution of risk scores for mortality
stratified by outcome at 2 months (stacked bar chart) and mortality risk (percent, shown by blue line) for (A) the full
risk score (based on the regression coefficients) and (B) the simplified risk score. Mortality risks and absolute numbers
in each category are presented in S2 Table.
https://doi.org/10.1371/journal.pmed.1002776.g003
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factors for mortality. These factors have been established as being associated with outcome in
HIV/TB in previous studies [24–28], and most likely reflect more advanced HIV-related
immunosuppression, late presentation to healthcare services, and/or poorer underlying physi-
ological reserve. Positive urine diagnostic tests (including LAM detection and Mycobacterium
tuberculosis nucleic acid detection) in the context of HIV infection are thought to represent
haematogenously disseminated renal TB with high mycobacterial burden, which may explain
why it is associated with a worse prognosis [34]. Interestingly, clinical signs and symptoms
(such as WHO danger signs) were not predictive of mortality.
In contrast to previously published data, ART-experienced patients had a higher mortality
risk in our study [28,35]. This likely reflects a high burden of unrecognised ART failure, due to
either poor adherence or drug resistance among patients admitted to hospital. Another poten-
tial cause is immune reconstitution inflammatory syndrome (IRIS) in patients who have
recently started ART. The relationship between ART and mortality is likely to be more com-
plex, representing different groups of patients with different mortality risks, but for this prag-
matic tool we have not been able to explore this further. CD4 cell count, which has been
previously shown to be associated with mortality in HIV-positive patients, dropped out of our
final multivariable predictive model due to mediation by other variables. Furthermore, in the
era of test and treat for HIV and use of quantitative HIV viral load for monitoring, CD4 testing
services are being scaled back, and are often not available in resource-limited settings.
Mechanisms and causes of mortality in advanced HIV/TB are still not well understood. Co-
pathologies, including other opportunistic infections and bacterial pneumonia or sepsis, are
commonly detected post-mortem [36,37]. High-risk patients could be prioritised for screening
for co-infections, for example using cryptococcal antigen point-of-care tests, or empirical pro-
phylactic treatment with antibacterial agents, an approach that has been shown to reduce mor-
tality in advanced HIV infection [38].
Whilst this clinical risk score can identify patients with the highest risk of mortality, there
remains an absence of proven interventions (beyond TB therapy and appropriately timed
ART) to reduce mortality in this population. Therefore, we propose this score could be used as
a clinical tool to alert clinicians to patients at high risk of mortality who should be reviewed
before discharge and/or flagged for early clinical follow-up in settings where urine TB-LAM
scale-up is occurring. The score could also be used as a research tool to aid evaluation of inten-
sified or optimised TB treatment regimens or adjunctive interventions aimed at reducing high
mortality in this population.
Possible interventions include rapid viral load testing with ART adherence support and
early switching for those with virological failure. Host-directed therapies, which target host
immune responses, are in clinical trials for TB, including some specifically for HIV/TB
[39,40]. Patients identified as being at highest risk for mortality could also be offered more
intensive monitoring or supportive care, for example better management of severe anaemia
[41], although optimal strategies of supportive care are not clear [42]. Enhanced treatment and
prophylaxis for co-infections have been shown to reduce early mortality in patients with
Fig 4. Observed mortality risk by risk score category in the derivation and validation cohorts. Observed mortality
risk (A) at 56 days, (B) during inpatient stay, and (C) post-discharge in the derivation and validation cohorts, stratified
by risk score category (derivation and validation cohorts) and simplified risk score category (derivation cohort).
Numbers on bars represent absolute mortality risk; error bars represent 95% confidence intervals. For the full risk
score, low risk was defined as 10 points or fewer, medium risk as 11 to 20 points, and high risk as more than 20 points.
For the simplified risk score, the low-risk group had a predictor score of 0 or 1 point, the medium-risk group had a
predictor score of 2 points, and the high-risk group had predictor score of�3 points. p-Values based on chi-squared
tests between groups for derivation and validation cohorts, respectively, are (A) p< 0.001 and p< 0.001, (B) p = 0.001
and p = 0.001, and (C) p = 0.015 and p = 0.003.
https://doi.org/10.1371/journal.pmed.1002776.g004
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advanced HIV initiating ART [38], and may also benefit those with HIV/TB disease. Interven-
tions will likely need to be instituted rapidly after TB diagnosis to alter outcomes.
The risk score was able to highlight patients at highest risk of death post-discharge, in addi-
tion to those at high risk of death during hospitalisation, and could be used to prevent too
early discharges. Enhanced community support, including home visits, has been shown to
reduce mortality after starting ART in advanced HIV [43], and could have a similar impact for
HIV/TB patients. Current services in high-burden settings take a public health approach to
service delivery, whereas prognostic risk scores can identify patients suitable for differentiated
care [8].
The main aim of this risk score was to detect patients at high risk of early mortality who
may benefit from interventions in addition to TB treatment. Although the discrimination of
the model was not perfect, the sensitivity of the simplified score was 75%; the score did not
identify 25% of patients who died within 2 months, and such patients would still receive stan-
dard-of-care management of HIV/TB. Proposed interventions to reduce mortality would have
limited adverse events, so those deemed as ‘high risk’ by the score but surviving to 2 months
are unlikely to come to significant harm from such interventions. However, if adjunctive inter-
ventions are found to reduce early mortality, better predictive biomarkers or more accurate
predictive tools would allow more efficient use of resources through targeting of patients.
Limitations of our study include the potential for selection bias. In the STAMP trial stan-
dard-of-care arm, only patients started on TB treatment for clinical/radiological criteria or fol-
lowing a positive sputum Xpert result had stored urine retrieved for TB testing. Patients with
otherwise undiagnosed TB who would have been urine test positive if they had been tested
were not included in this study. Patients unable to provide consent, mostly due to being
severely unwell and having altered consciousness, were also excluded. Although our risk score
did not have optimal discrimination and calibration, performance was adequate and similar to
that of other prognostic scores widely used in clinical practice (e.g., the Framingham cardio-
vascular risk score) [15,44]. Performance may have been reduced by categorising continuous
variables for simplicity. TB drug resistance was not a predictor of mortality in this cohort;
however, prevalence of rifampicin resistance was low in these settings. Not all established risk
factors for mortality were characterised, leaving potential to improve on performance. Future
studies could assess more detailed markers of physiology, as well as social and more distal risk
factors.
Whilst the score is pragmatic and its constituent factors are widely available in hospitals in
African regions with high HIV and TB burdens, it does rely on access to the TB-LAM lateral
flow assay. There is now good evidence to support mortality reductions with the use of
TB-LAM in HIV-positive patients admitted to hospital [4,5], and its use as a screening test has
been incorporated into the latest guidelines in Malawi and South Africa. The assay has also
been scaled up nationally in eSwatini, Kenya, and Uganda [45]. Missing data were common in
the validation cohort. However, sensitivity analyses using multiple imputation gave similar
results as the complete case analysis. We assumed patients lost to follow-up were alive at 2
months, although only 2% in the derivation cohort and 4% in the validation cohort were not
followed up after hospital discharge. Our cohort did not include patients treated for TB with-
out a positive diagnostic test, which remains common in HIV-positive patients admitted to
hospital, and this patient group may be an important group for whom to apply risk
Fig 5. Survival curves stratified by clinical risk score category in the derivation dataset. Survival curves and risk tables with
number at risk for the (A) derivation cohort and (B) validation cohort stratified by risk group using the simplified clinical risk score.
The low-risk group (blue line) had a risk score of 0 or 1 point, the medium-risk group (red line) had a risk score of 2 points, and the
high-risk group (green line) had a risk score of�3 points. Log-rank test p< 0.001.
https://doi.org/10.1371/journal.pmed.1002776.g005
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stratification and predictive scores. The biomarkers studied are imperfect predictors of mortal-
ity, and further research is needed to focus on better biomarkers to predict outcome.
Strengths of this study include that the derivation cohort and the LAM-RCT external vali-
dation cohort were nested within randomised controlled trials. Our predictive model had sim-
ilar discrimination and calibration in the validation cohort, and was able to identify groups of
patients with similarly increased odds of mortality. This was despite the validation cohort
being from geographically distinct locations, collected at different times by different investiga-
tors, and with a lower overall mortality risk at 2 months. The factors required for the score can
be obtained rapidly after admission.
In conclusion, we have developed and externally validated a clinical risk score capable of
identifying, among patients admitted to hospital in settings with high HIV/TB burden, those
with the highest risk of early mortality. This score could be a useful clinical and research tool,
and could prove beneficial in identifying patients who would gain most from adjunctive inter-
ventions to reduce mortality. Further work to assess the impact of such risk scores, and to
identify which interventions could potentially reduce mortality, is urgently needed if ambi-
tious global targets to reduce TB mortality are to be met by 2025.
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